Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab versus interferon beta-1a in relapsing multiple sclerosis previously treated with interferon beta-1a
2004-004130-14Phase 3Completed
- Sponsor
- Biogen Idec GmbH
- Start
- Jan 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in multiple sclerosis (MS) comparing Natalizumab with Interferon beta-1a (2 arms). Primary endpoint: Annualized rate of clinical relapses at 1 year. Started Jan 2005; status: completed.
02
Drugs
natalizumabinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2004-004130-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004130-14.